Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection

Retrovirology

Volumn 8, Issue , 2011, Pages

  Willey, Suzanne ^a,b   Aasa Chapman, Marlén M I ^a   O'Farrell, Stephen ^c   Pellegrino, Pierre ^c   Williams, Ian ^c   Weiss, Robin A ^a   Neil, Stuart J D ^a,b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; COMPLEMENT MEDIATED ANTIBODY DEPENDENT ENHANCEMENT; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONGITUDINAL STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; ANTIBODY DEPENDENT ENHANCEMENT; BLOOD; CELL LINE; COMPLEMENT ACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PATHOPHYSIOLOGY; SERODIAGNOSIS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; NEUTRALIZATION TESTS; RECEPTORS, COMPLEMENT 3D; T-LYMPHOCYTES;

EID: 79952529988     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-16     Document Type: Article

References (111)

1. Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, Balfe P, McKnight A. Development of the antibody response in acute HIV-1 infection. Aids 2004, 18:371-381. 10.1097/00002030-200402200-00002, 15090788.
2. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, et al. Initial B Cell Responses to Transmitted HIV-1: Virion-Binding IgM and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. J Virol 2008, 82:12449-12463. 10.1128/JVI.01708-08, 2593361, 18842730.
3. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997, 71:3734-3741. 191523, 9094648.
4. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100:4144-4149. 10.1073/pnas.0630530100, 153062, 12644702.
5. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312. 10.1038/nature01470, 12646921.
6. Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, Pellegrino P, Newton P, Williams I, Borrow P, McKnight A. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 2005, 79:2823-2830. 10.1128/JVI.79.5.2823-2830.2005, 548453, 15709001.
7. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006, 80:5211-5218. 10.1128/JVI.00201-06, 1472127, 16699001.
8. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007, 81:6187-6196. 10.1128/JVI.00239-07, 1900112, 17409164.
9. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005, 102:18514-18519. 10.1073/pnas.0504658102, 1310509, 16339909.
10. Kelly HR, Urbanski M, Burda S, Zhong P, Konings F, Nanfack J, Tongo M, Kinge T, Achkar J, Nyambi P. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals. Hum Antibodies 2005, 14:89-99.
11. Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol 2008, 16:596-604. 10.1016/j.tim.2008.08.008, 18964020.
12. Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S, Wang M, Parren PW, Burton DR. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 2003, 77:353-365. 10.1128/JVI.77.1.353-365.2003, 140593, 12477840.
13. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991, 174:1417-1424. 10.1084/jem.174.6.1417, 2119058, 1744579.
14. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. Aids 1993, 7:1307-1313. 10.1097/00002030-199310000-00002, 8267903.
15. Susal C, Kirschfink M, Kropelin M, Daniel V, Opelz G. Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120. Blood 1996, 87:2329-2336.
16. Stoiber H, Thielens NM, Ebenbichler C, Arlaud GJ, Dierich MP. The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol 1994, 24:294-300. 10.1002/eji.1830240203, 7507842.
17. Marschang P, Kruger U, Ochsenbauer C, Gurtler L, Hittmair A, Bosch V, Patsch JR, Dierich MP. Complement activation by HIV-1-infected cells: the role of transmembrane glycoprotein gp41. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:102-109.
18. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993, 67:53-59. 237336, 7677959.
19. Thieblemont N, Haeffner-Cavaillon N, Weiss L, Maillet F, Kazatchkine MD. Complement activation by gp160 glycoprotein of HIV-1. AIDS Res Hum Retroviruses 1993, 9:229-233. 10.1089/aid.1993.9.229, 8471312.
20. Saarloos MN, Lint TF, Spear GT. Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells. Clin Exp Immunol 1995, 99:189-195. 10.1111/j.1365-2249.1995.tb05531.x, 1534296, 7851010.
21. Speth C, Kacani L, Dierich MP. Complement receptors in HIV infection. Immunol Rev 1997, 159:49-67. 10.1111/j.1600-065X.1997.tb01006.x, 9416502.
22. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001, 75:6953-6961. 10.1128/JVI.75.15.6953-6961.2001, 114423, 11435575.
23. Forthal DN, Landucci G, Phan TB, Becerra J. Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. J Virol 2005, 79:2042-2049. 10.1128/JVI.79.4.2042-2049.2005, 546539, 15681406.
24. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B, Weber R, von Wyl V, Gunthard HF, Trkola A. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 2006, 3:e441. 10.1371/journal.pmed.0030441, 1637124, 17121450.
25. Szabo J, Prohaszka Z, Toth FD, Gyuris A, Segesdi J, Banhegyi D, Ujhelyi E, Minarovits J, Fust G. Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. Aids 1999, 13:1841-1849. 10.1097/00002030-199910010-00005, 10513641.
26. Sullivan BL, Knopoff EJ, Saifuddin M, Takefman DM, Saarloos MN, Sha BE, Spear GT. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol 1996, 157:1791-1798.
27. Sullivan BL, Takefman DM, Spear GT. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology 1998, 248:173-181. 10.1006/viro.1998.9289, 9721226.
28. Robinson WE, Montefiori DC, Mitchell WM. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990, 175:600-604. 10.1016/0042-6822(90)90449-2, 2327077.
29. Bajtay Z, Speth C, Erdei A, Dierich MP. Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3, CD11b/CD18). J Immunol 2004, 173:4775-4778.
30. Beck Z, Prohaszka Z, Fust G. Traitors of the immune system-Enhancing antibodies in HIV infection: Their possible implication in HIV vaccine development. Vaccine 2008, 26:3078-3085. 10.1016/j.vaccine.2007.12.028, 18241961.
31. Fust G, Toth FD, Kiss J, Ujhelyi E, Nagy I, Banhegyi D. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS 1994, 8:603-609. 10.1097/00002030-199405000-00005, 7914732.
32. Robinson WE, Montefiori DC, Gillespie DH, Mitchell WM. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr 1989, 2:33-42.
33. Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 2001, 260:145-169.
34. Robinson WE, Kawamura T, Gorny MK, Lake D, Xu JY, Matsumoto Y, Sugano T, Masuho Y, Mitchell WM, Hersh E, et al. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci USA 1990, 87:3185-3189. 10.1073/pnas.87.8.3185, 53860, 2326277.
35. Bouhlal H, Galon J, Kazatchkine MD, Fridman WH, Sautes-Fridman C, Haeffner Cavaillon N. Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J Immunol 2001, 166:3377-3383.
36. Pruenster M, Wilflingseder D, Banki Z, Ammann CG, Muellauer B, Meyer M, Speth C, Dierich MP, Stoiber H. C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur J Immunol 2005, 35:2691-2698. 10.1002/eji.200425940, 16094691.
37. Wilflingseder D, Banki Z, Garcia E, Pruenster M, Pfister G, Muellauer B, Nikolic DS, Gassner C, Ammann CG, Dierich MP, et al. IgG opsonization of HIV impedes provirus formation in and infection of dendritic cells and subsequent long-term transfer to T cells. J Immunol 2007, 178:7840-7848.
38. Bouhlal H, Chomont N, Requena M, Nasreddine N, Saidi H, Legoff J, Kazatchkine MD, Belec L, Hocini H. Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol 2007, 178:1086-1095.
39. Prohaszka Z, Nemes J, Hidvegi T, Toth FD, Kerekes K, Erdei A, Szabo J, Ujhelyi E, Thielens N, Dierich MP, et al. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. Aids 1997, 11:949-958. 10.1097/00002030-199708000-00002, 9223728.
40. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003, 13:387-398. 10.1002/rmv.405, 14625886.
41. Lund O, Hansen J, Soorensen AM, Mosekilde E, Nielsen JO, Hansen JE. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J Virol 1995, 69:2393-2400. 188912, 7884885.
42. Robinson WE. Mechanism for complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors. Viral Immunol 2006, 19:434-447. 10.1089/vim.2006.19.434, 16987062.
43. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994, 19:500-512. 10.1093/clinids/19.3.500, 7811870.
44. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988, 239:476-481. 10.1126/science.3277268, 3277268.
45. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989, 40:444-451.
46. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, Dung NT, Lien le B, Quy NT, Hieu NT, Hieu LT, et al. Dengue in Vietnamese infants--results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 2008, 198:516-524. 10.1086/590117, 2730540, 18598189.
47. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328:745-748. 10.1126/science.1185181, 20448183.
48. Wallace MJ, Smith DW, Broom AK, Mackenzie JS, Hall RA, Shellam GR, McMinn PC. Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 2003, 84:1723-1728. 10.1099/vir.0.18980-0, 12810865.
49. Ponnuraj EM, Springer J, Hayward AR, Wilson H, Simoes EA. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J Infect Dis 2003, 187:1257-1263. 10.1086/374604, 12696005.
50. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003, 77:7539-7544. 10.1128/JVI.77.13.7539-7544.2003, 164833, 12805454.
51. Iankov ID, Pandey M, Harvey M, Griesmann GE, Federspiel MJ, Russell SJ. Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 2006, 80:8530-8540. 10.1128/JVI.00593-06, 1563851, 16912303.
52. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 2006, 168:1210-1226. 10.2353/ajpath.2006.050482, 1606573, 16565496.
53. Hosie MJ, Osborne R, Reid G, Neil JC, Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 1992, 35:191-197. 10.1016/0165-2427(92)90131-9, 1337397.
54. Lombardi S, Garzelli C, Pistello M, Massi C, Matteucci D, Baldinotti F, Cammarota G, da Prato L, Bandecchi P, Tozzini F, et al. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol 1994, 68:8374-8379. 237306, 7966629.
55. Siebelink KH, Tijhaar E, Huisman RC, Huisman W, de Ronde A, Darby IH, Francis MJ, Rimmelzwaan GF, Osterhaus AD. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 1995, 69:3704-3711. 189086, 7745719.
56. Richardson J, Moraillon A, Baud S, Cuisinier AM, Sonigo P, Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 1997, 71:9640-9649. 230272, 9371628.
57. Giannecchini S, Isola P, Sichi O, Matteucci D, Pistello M, Zaccaro L, Del Mauro D, Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J Virol 2002, 76:6882-6892. 10.1128/JVI.76.14.6882-6892.2002, 136316, 12072489.
58. Mitchell WM, Torres J, Johnson PR, Hirsch V, Yilma T, Gardner MB, Robinson WE. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. Aids 1995, 9:27-34. 10.1097/00002030-199501000-00004, 7893438.
59. Staprans SI, Barry AP, Silvestri G, Safrit JT, Kozyr N, Sumpter B, Nguyen H, McClure H, Montefiori D, Cohen JI, Feinberg MB. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 2004, 101:13026-13031. 10.1073/pnas.0404739101, 516468, 15326293.
60. Wang SZ, Rushlow KE, Issel CJ, Cook RF, Cook SJ, Raabe ML, Chong YH, Costa L, Montelaro RC. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 1994, 199:247-251. 10.1006/viro.1994.1120, 8116252.
61. Hammond SA, Raabe ML, Issel CJ, Montelaro RC. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 1999, 262:416-430. 10.1006/viro.1999.9939, 10502520.
62. Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994, 205:82-92. 10.1006/viro.1994.1622, 7526538.
63. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995, 182:501-509. 10.1084/jem.182.2.501, 2192116, 7543140.
64. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, Shiramizu B, Halperin JA, Qin X. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 2010, 184:359-368. 10.4049/jimmunol.0902278, 19955519.
65. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10:11-23. 10.1038/nri2674, 20010788.
66. Banhegyi D, Bacsi A, Toth FD, Prohaszka Z, Horvath A, Beck Z, Konya J, Fust G. Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART). Immunol Lett 2003, 89:25-30. 10.1016/S0165-2478(03)00106-8, 12946861.
67. Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, et al. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3 d interface. J Immunol 2001, 167:5758-5766.
68. Petzer AL, Schulz TF, Stauder R, Eigentler A, Myones BL, Dierich MP. Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion. Immunology 1988, 63:47-53. 1454684, 2448232.
69. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977, 265:739-741. 10.1038/265739a0, 404559.
70. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977, 146:201-217. 10.1084/jem.146.1.201, 2180729, 406347.
71. Stoiber H, Banki Z, Wilflingseder D, Dierich MP. Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 2007, 26:3046-3054. 10.1016/j.vaccine.2007.12.003, 18191309.
72. Doepper S, Stoiber H, Kacani L, Sprinzl G, Steindl F, Prodinger WM, Dierich MP. B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: role of complement. Immunobiology 2000, 202:293-305.
73. Kacani L, Prodinger WM, Sprinzl GM, Schwendinger MG, Spruth M, Stoiber H, Dopper S, Steinhuber S, Steindl F, Dierich MP. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol 2000, 74:7997-8002. 10.1128/JVI.74.17.7997-8002.2000, 112331, 10933708.
74. Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, Baseler M, Ehler LA, Liu S, Davey RT, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med 2000, 192:637-646. 10.1084/jem.192.5.637, 2193277, 10974030.
75. Dopper S, Wilflingseder D, Prodinger WM, Stiegler G, Speth C, Dierich MP, Stoiber H. Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures. Eur J Immunol 2003, 33:2098-2107. 10.1002/eji.200323932, 12884283.
76. Banki Z, Kacani L, Rusert P, Pruenster M, Wilflingseder D, Falkensammer B, Stellbrink HJ, van Lunzen J, Trkola A, Dierich MP, Stoiber H. Complement dependent trapping of infectious HIV in human lymphoid tissues. Aids 2005, 19:481-486. 10.1097/01.aids.0000162336.20439.8d, 15764853.
77. Ho J, Moir S, Kulik L, Malaspina A, Donoghue ET, Miller NJ, Wang W, Chun TW, Fauci AS, Holers VM. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol 2007, 178:6968-6974.
78. Keele BF, Tazi L, Gartner S, Liu Y, Burgon TB, Estes JD, Thacker TC, Crandall KA, McArthur JC, Burton GF. Characterization of the Follicular Dendritic Cell Reservoir of HIV-1. J Virol 2008, 82:5548-5561. 10.1128/JVI.00124-08, 2395176, 18385252.
79. Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 1991, 146:865-869.
80. June RA, Landay AL, Stefanik K, Lint TF, Spear GT. Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons. Immunology 1992, 75:59-65. 1384803, 1371493.
81. Levy E, Ambrus J, Kahl L, Molina H, Tung K, Holers VM. T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol 1992, 90:235-244. 10.1111/j.1365-2249.1992.tb07935.x, 1554594, 1424280.
82. Fischer EM, Mouhoub A, Maillet F, Fremeaux-Bacchi V, Krief C, Gould H, Berrih-Aknin S, Kazatchkine MD. Expression of CD21 is developmentally regulated during thymic maturation of human T lymphocytes. Int Immunol 1999, 11:1841-1849. 10.1093/intimm/11.11.1841, 10545488.
83. Sandilands GP, Perry M, Wootton M, Hair J, More IA. B-cell antigens within normal and activated human T cells. Immunology 1999, 96:424-433. 10.1046/j.1365-2567.1999.00692.x, 2326768, 10233724.
84. Masilamani M, von Seydlitz E, Bastmeyer M, Illges H. T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3 d receptor (CR2/CD21) gene and protein expression. Immunobiology 2002, 206:528-536. 10.1078/0171-2985-00201, 12607728.
85. Tsoukas CD, Lambris JD. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol 1988, 18:1299-1302. 10.1002/eji.1830180823, 2970972.
86. Delibrias CC, Mouhoub A, Fischer E, Kazatchkine MD. CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur J Immunol 1994, 24:2784-2788. 10.1002/eji.1830241131, 7957570.
87. Gasque P, Chan P, Mauger C, Schouft MT, Singhrao S, Dierich MP, Morgan BP, Fontaine M. Identification and characterization of complement C3 receptors on human astrocytes. J Immunol 1996, 156:2247-2255.
88. Leslie RG. Complement Receptors. Encyclopedia of Life Sciences 2001, Nature Publishing Group.
89. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin AM, Moog C. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006, 80:6177-6181. 10.1128/JVI.02625-05, 1472578, 16731957.
90. Montefiori DC, Reimann KA, Letvin NL, Zhou J, Hu SL. Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. AIDS Res Hum Retroviruses 1995, 11:963-970. 10.1089/aid.1995.11.963, 7492443.
91. Robinson WE, Gorny MK, Xu JY, Mitchell WM, Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 1991, 65:4169-4176. 248851, 2072448.
92. Mitchell WM, Ding L, Gabriel J. Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV. Aids 1998, 12:147-156. 10.1097/00002030-199802000-00004, 9468363.
93. Burrer R, Haessig-Einius S, Aubertin AM, Moog C. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology 2005, 333:102-113. 10.1016/j.virol.2004.12.034, 15708596.
94. Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, Moore JP, Raina JL, Renz H, Gelderblom HR, Nara PL. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992, 189:695-714. 10.1016/0042-6822(92)90593-E, 1386485.
95. Piatak M, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754. 10.1126/science.8096089, 8096089.
96. Finzi D, Plaeger SF, Dieffenbach CW. Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis. Clin Vaccine Immunol 2006, 13:715-721. 10.1128/CVI.00052-06, 1489566, 16829607.
97. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: another look. Trends Microbiol 1999, 7:144-149. 10.1016/S0966-842X(99)01474-2, 10217828.
98. Zhu P, Chertova E, Bess J, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci USA 2003, 100:15812-15817. 10.1073/pnas.2634931100, 307650, 14668432.
99. Thomas JA, Ott DE, Gorelick RJ. Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions. J Virol 2007, 81:4367-4370. 10.1128/JVI.02357-06, 1866140, 17267494.
100. Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007, 131:1059-1071. 10.1016/j.cell.2007.10.014, 18083097.
101. Fortin JF, Cantin R, Lamontagne G, Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997, 71:3588-3596. 191506, 9094631.
102. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597. 10.1016/S0092-8674(00)80694-7, 10721995.
103. Lee B, Leslie G, Soilleux E, O'Doherty U, Baik S, Levroney E, Flummerfelt K, Swiggard W, Coleman N, Malim M, Doms RW. cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J Virol 2001, 75:12028-12038. 10.1128/JVI.75.24.12028-12038.2001, 116098, 11711593.
104. McKeating JA, McKnight A, McIntosh K, Clapham PR, Mulder C, Weiss RA. Evaluation of human and simian immunodeficiency virus plaque and neutralization assays. J Gen Virol 1989, 70(Pt 12):3327-3333. 10.1099/0022-1317-70-12-3327, 2575137.
105. Barbas CF, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992, 89:9339-9343. 10.1073/pnas.89.19.9339, 50122, 1384050.
106. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765. 10.1089/08892220152741450, 11788027.
107. Soda Y, Shimizu N, Jinno A, Liu HY, Kanbe K, Kitamura T, Hoshino H. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 1999, 258:313-321. 10.1006/bbrc.1999.0633, 10329384.
108. Montefiori D. Protocol for Measuring Neutralizing Antibodies Against HIV-1, SIV and SHIV Using a Luciferase Reporter Gene Assay in TZM-BL Cells. 2008, http://www.hivlanlgov/content/nab-reference-strains/html/Protocol-Neutralizing-Antibody-Assay-for-HIV-1-in-TZM-bl-Cells-July-2008pdf
109. Barrault DV, Knight AM. Distinct sequences in the cytoplasmic domain of complement receptor 2 are involved in antigen internalization and presentation. J Immunol 2004, 172:3509-3517.
110. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, Grez M, Thrasher AJ. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002, 13:803-813. 10.1089/10430340252898984, 11975847.
111. Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 2008, 89:2204-2213. 10.1099/vir.0.2008/000349-0, 2886951, 18753230.